1. Introduction {#sec1}
===============

Gastric cancer is the second leading cause of cancer-related mortality and the fourth most common cancer globally \[[@B1]\]. In 2014, 410,400 new stomach cancer cases and 293,800 cancer-associated deaths were estimated to have occurred in China. The crude incidence rate of stomach cancer was 30.00/100,000, and the crude mortality rate of stomach cancer was 21.48/100,000 \[[@B2]\]. As many factors impact gastric cancer prognosis, identifying important biomarkers of gastric cancer will have a great influence for patients.

Small heat shock protein (sHSP) is a group of proteins, which express ubiquitously from prokaryotes to eukaryotes. HSP27 exists as a multimeric complex in the cells and serves functions, like refolding of unfolded proteins, regulation of cytoskeleton dynamics, and cell cycle regulation. sHSPs bind to a wide range of cellular proteins and are implicated in several cellular functions, apart from providing protection against various environmental and physical stressors, such as high temperature and chemical toxins \[[@B3]\].

High expression levels of HSP have been reported in many cancers, including breast, head and neck, gallbladder, colorectal, skin, liver, colon, renal, prostate, and ovarian cancer \[[@B4], [@B5]\]. Of particular interest, HSPs play dual complex role in apoptosis via promoting or counteracting cell death. For instance, HSPs have been shown to activate apoptotic mediators such as procaspase 3 \[[@B6], [@B7]\], and conversely, they bind and inhibit several molecules at different levels in the apoptotic pathway \[[@B8]\]. The antiapoptotic events include the blockade of cytochrome C release from the mitochondria by HSP27 besides antagonizing caspase 3 and caspase 9 \[[@B9]--[@B11]\]. HSP27 can also suppress other apoptotic death receptor pathways, including TNF*α*, Fas, and TRAIL \[[@B12]\].

HSP27 is reported to be a major target in combating cancer. An increased level of HSP27 is reported in different cancers, including breast cancer, endometrial cancer, and leukemia \[[@B3]\]. Although several studies have reported the relationship between HSP27 and gastric cancer, the conclusions are controversial and the patients included in each study are not enough. Therefore, we conducted meta-analysis of those studies to explore the relationship between HSP27 expression and clinicopathological feature of gastric cancer.

2. Methods and Materials {#sec2}
========================

As there was a meta-analysis study published before about relationship between HSP27 expression and clinicopathological feature of gastric cancer, we referred to relevant content about method and material of the study \[[@B13]\].

2.1. Identification and Eligibility of Relevant Studies {#sec2.1}
-------------------------------------------------------

We searched PubMed, Chinese CNKI, and WanFang databases to identify studies that assessed the association between clinicopathological feature and HSP27 expression in gastric cancer patients. The search ended in September 1, 2019. Search words were "heat shock protein 27," "HSP27," "gastric cancer," "gastric carcinoma," and "stomach neoplasm."

The included criteria for this study were as follows: (1) patients were diagnosed as gastric cancer; (2) HSP27 expression was tested in tissue of gastric patients by immunohistochemistry (IHC); (3) study design was case-control study or cross-sectional study; (4) studies included at least one primary outcome of interest; and (5) study was published in English or Chinese with full text available.

The excluded criteria for this study were as follows: (1) letters, reviews, conference abstracts, animal experiments, fundamental research, and duplicated studies were excluded; (2) studies that did not estimate the relationship of HSP27 expression and clinicopathological feature were excluded; and (3) studies whose data could not be used for meta-analysis were excluded.

2.2. Data Extraction {#sec2.2}
--------------------

Two reviewers independently screened all studies to determine the relevant articles meeting the included criteria. Extracted data included the first author\'s name, publication year, sample size, country, and clinicopathologial features (HSP27 expression, gender, differentiation, lymph node metastasis, and distant metastasis). Disagreements were resolved by the third-party adjudication.

2.3. Quality Assessment {#sec2.3}
-----------------------

The quality of each included case-control study was assessed by the Newcastle--Ottawa scale (NOS), while the quality of cross-sectional study included was assessed by the Agency for Healthcare Research and Quality (AHRQ). Studies with NOS score ≥6 were considered as good quality and with NOS score ＜5 were considered as poor quality. Studies with AHRQ score 8--11 were as good quality, with AHRQ score 4--7 were as moderate quality, and with AHRQ score 0--3 were as poor quality.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Review manager 5.3 software was used to perform the statistical analysis for these meta-analyses. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the association between HSP27 expression and clinicopathological feature. The heterogeneity was evaluated by the *I*^2^ test. Fixed effects model was used when there was no significant heterogeneity (*I*^2^ ＜ 50%, *P* ≥ 0.1), while the random effect model was chosen if there was significant heterogeneity (*I*^2^ ≥ 50%, *P* \< 0,1).

3. Results {#sec3}
==========

3.1. Eligible Studies {#sec3.1}
---------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, we identified 154 records from PubMed, CNKI, and WanFang databases. After excluding the duplicates and irrelevant studies, 25 studies remained to review the abstracts and full text to find available data. As some data in those studies could not be used, finally, we got 13 studies to conduct meta-analysis to evaluate the relationship between HSP27 expression and clinicopathological feature \[[@B14]--[@B26]\].

The characteristics of included studies are shown in [Table 1](#tab1){ref-type="table"}. We got 758 gastric patients, 256 paracancerous tissue specimens, and 230 normal tissue specimens. The included studies were published from 2001 to 2017 and conducted in different countries (ten in China, one in Jordan, one in Japan, and one in Greece). Based on NOS or AHRQ scores, 11 studies were evaluated as good quality, while 2 studies were as moderate quality.

3.2. Meta-Analysis {#sec3.2}
------------------

We extracted available data from included studies to conduct meta-analysis. As shown in [Table 2](#tab2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}, we assessed the relationship between expression of HSP27 expression and clinicopathological feature of gastric cancer. We found overexpression of HSP27 was associated with incidence of gastric cancer (OR = 6.31, 95% CI = 1.10--36.15, *P* \< 0.0001). However, there was no significant difference between HSP27 expression and gastric cancer differentiation (OR = 1.14, 95% CI = 0.52--2.52, *P*=0.74), gender difference (OR = 0.95, 95% CI = 0.62--1.48), lymph node metastasis (OR = 1.44, 95% CI = 0.66--3.16, *P*=0.36), and distant metastasis (OR = 0.64, 95% CI = 0.10--4.09, *P*=0.64).

3.3. Publication Bias {#sec3.3}
---------------------

As shown in [Figure 3](#fig3){ref-type="fig"}, we used the funnel plot to assess the publication bias, and we found that there was no significant asymmetry about HSP27 expression in comparison between gastric cancer and normal tissue, male and female, lymph node metastasis and nonlymph node metastasis, and distant metastasis and nondistant metastasis.

4. Discussion {#sec4}
=============

We compared our results with previous meta-analysis of the association between HSP27 expression and clinicopathological feature of gastric cancer, which included 9 articles \[[@B13]\]. In our study, we included 13 articles to extract more available data to conduct meta-analysis. Although we added 4 more articles in this meta-analysis based on previous study, we finally got similar results as before. There was statistical significance between overexpression of HSP27 and incidence of gastric cancer. However, we still did not find significance of HSP27 expression in gastric cancer differentiation, genders, lymph node, and distant metastasis.

Previous meta-analysis study combined normal tissue and gastric carcinoma adjacent tissue as the control group. However, considering the difference between normal tissue and gastric carcinoma adjacent tissue, we compared the gastric carcinoma with normal tissue or gastric carcinoma adjacent tissue, respectively. To our surprise, we found there was publication bias in comparison between gastric cancer and its adjacent tissue. The reason might be the different way of choosing and punching biopsy.

As a protein chaperone, HSP27 had many functions in cell, such as antiapoptosis and protecting cell. There were several reports indicating that HSP27 was upregulated in many cancers. Some studies even suggested HSP27 was associated with poor prognosis and was drug resistant, as it could protect tumor cell from apoptosis induced by drugs \[[@B27]\]. In summary, HSP27 might play an important role in cancer therapy and become a new target for treatment in the future.

5. Conclusion {#sec5}
=============

Our meta-analysis study indicates that overexpression of HSP27 is associated with incidence of gastric cancer statistically. However, more high-quality research studies with a large sample size should be conducted in future.
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###### 

Characteristics of studies included in this meta-analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                   Year   Country   Study design   No. of samples   Age   Gender: male (±)\   HSP27 expression: gastric cancer (±)\   Differentiation: low (±)\   Lymph node metastasis: metastasis (±)\   Distant metastasis: metastasis (±)\   Quality score           
                                                                                  female (±)          adjacent tissue (±)\                    high and middle (±)         nonmetastasis (±)                        nonmetastasis (±)                                             
                                                                                                      control (±)                                                                                                                                                                
  ------------------------ ------ --------- -------------- ---------------- ----- ------------------- --------------------------------------- --------------------------- ---------------------------------------- ------------------------------------- --------------- ------- ---
  Li et al.                2010   China     ROS            45               30    20                  29--70                                  15/8\                       31/14\                                   9/18\                                 18/11\          NA      8
                                                                                                                                              16/6                        8/22                                     22/27                                 13/3                    

  Tang et al.              2009   China     ROS            34               34    34                  32--84                                  NA                          18/16\                                   NA                                    NA              NA      6
                                                                                                                                                                          4/30                                                                                                   

  Song et al.              2009   China     ROS            41               NA    NA                  60--77                                  NA                          NA                                       3/8\                                  NA              NA      6
                                                                                                                                                                                                                   9/21                                                          

  Li et al.                2012   China     ROS            48               NA    14                  30--75                                  NA                          31/17                                    25/11\                                29/10\          5/1\    8
                                                                                                                                                                                                                   6/6                                   2/7             26/16   

  Hu et al.                2015   China     ROS            75               75    NA                  23--78                                  35/18\                      43/32\                                   32/9\                                 32/9\           NA      7
                                                                                                                                              13/9                        62/13                                    16/18                                 16/18                   

  Wen et al.               2017   China     ROS            20               NA    NA                  22--86                                  NA                          NA                                       2/2\                                  NA              NA      7
                                                                                                                                                                                                                   15/1                                                          

  Song et al.              2001   China     ROS            54               NA    NA                  20--83                                  NA                          NA                                       7/10\                                 NA              NA      7
                                                                                                                                                                                                                   11/19                                                         

  Bo et al.                2003   China     CSS            98               NA    NA                  36--78                                  NA                          49/49                                    6/15\                                 20/19\          NA      5
                                                                                                                                                                                                                   39/30                                 29/30                   

  Lu et al.                2007   China     ROS            68               57    NA                  35--76                                  18/19\                      32/36\                                   4/11\                                 10/15\          NA      7
                                                                                                                                              14/17                       15/42\                                   28/25                                 22/21                   
                                                                                                                                                                          44/16                                                                                                  

  Shang et al.             2012   China     ROS            60               60    60                  33--81                                  31/12\                      6/54\                                    30/16\                                30/13\          0/3\    7
                                                                                                                                              13/4                        3/57                                     6/8                                   14/3            43/14   

  Khaldon Bodoor et al.    2016   Jordan    ROS            87               NA    16                  25--98                                  NA                          66/21\                                   NA                                    NA              NA      8
                                                                                                                                                                          14/2                                                                                                   

  Shinsuke Takeno et al.   2001   Japan     CSS            42               NA    NA                  42--85                                  15/11\                      NA                                       NA                                    NA              NA      6
                                                                                                                                              7/9                                                                                                                                

  Kapranos                 2002   Greece    ROS            86               NA    86                  37--85                                  25/19\                      NA                                       NA                                    48/23\          NA      7
                                                                                                                                              29/13                                                                                                      6/9                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

The odds ratio between HSP27 expression and clinicopathological feature of gastric cancer.

  Clinicopathological features   Heterogeneity                                                                               
  ------------------------------ ---------------- ----- -------------------- -------------------- ------- ------ ----------- --------
  HSP27 expression               GC vs AT         5     173                  6.25 (2.88, 13.57)   0.008   71     \<0.00001   Random
  GC vs NT                       4                159   6.31 (1.10, 36.15)   \<0.0001             86      0.04   Random      
  Differentiation                PD vs HMD        9     270                  1.14 (0.52, 2.52)    0.001   69     0.74        Random
  Gender                         Male vs female   6     231                  0.95 (0.62, 1.48)    0.71    0      0.83        Fixed
  Lymph node metastasis          N1-3 vs N0       7     289                  1.44 (0.66, 3.16)    0.004   69     0.36        Random
  Distant metastasis             M1 vs M0         3     96                   0.64 (0.10, 4.09)    0.09    58     0.64        Random

Abbreviations: GC, gastric cancer; AT, adjacent tissue; NT, normal tissue; PD, poor differentiation; HMD, high or moderate differentiation; random, random effect model; fixed, fixed effect model; OR, odds ratio; CI, conference interval.
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